Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
3.220
+0.110 (3.54%)
At close: Nov 4, 2024, 4:00 PM
3.140
-0.080 (-2.48%)
After-hours: Nov 4, 2024, 4:01 PM EST
Vistagen Therapeutics Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 |
Revenue | 0.97 | 1.06 | -0.23 | 1.11 | 1.09 | - | |
Revenue Growth (YoY) | - | - | - | 1.78% | - | - | |
Gross Profit | 0.97 | 1.06 | -0.23 | 1.11 | 1.09 | - | |
Selling, General & Admin | 15.65 | 14.06 | 14.66 | 13.96 | 7.64 | 7.96 | |
Research & Development | 23.47 | 20.02 | 44.38 | 34.92 | 11.38 | 12.84 | |
Operating Expenses | 39.13 | 34.09 | 59.04 | 48.89 | 19.02 | 20.8 | |
Operating Income | -38.15 | -33.02 | -59.27 | -47.78 | -17.93 | -20.8 | |
Interest Expense | - | - | - | - | -0.01 | -0.01 | |
Interest & Investment Income | 4.65 | 3.35 | 0.03 | 0.02 | 0.02 | 0.05 | |
Other Non Operating Income (Expenses) | 0.31 | 0.31 | - | - | 0 | - | |
EBT Excluding Unusual Items | -33.19 | -29.36 | -59.24 | -47.76 | -17.93 | -20.77 | |
Pretax Income | -33.19 | -29.36 | -59.24 | -47.76 | -17.93 | -20.77 | |
Income Tax Expense | 0 | 0 | 0.01 | 0 | 0 | 0 | |
Net Income | -33.19 | -29.36 | -59.25 | -47.76 | -17.93 | -20.77 | |
Preferred Dividends & Other Adjustments | - | - | - | 0.95 | 24.39 | 1.26 | |
Net Income to Common | -33.19 | -29.36 | -59.25 | -48.71 | -42.32 | -22.04 | |
Shares Outstanding (Basic) | 25 | 19 | 7 | 7 | 3 | 1 | |
Shares Outstanding (Diluted) | 25 | 19 | 7 | 7 | 3 | 1 | |
Shares Change (YoY) | 255.96% | 178.13% | 5.45% | 129.85% | 96.34% | 53.59% | |
EPS (Basic) | -1.32 | -1.52 | -8.51 | -7.38 | -14.74 | -15.07 | |
EPS (Diluted) | -1.32 | -1.52 | -8.51 | -7.38 | -14.74 | -15.07 | |
Free Cash Flow | -28.89 | -25.87 | -49.93 | -45.46 | -12.35 | -15.76 | |
Free Cash Flow Per Share | -1.15 | -1.34 | -7.17 | -6.89 | -4.30 | -10.78 | |
Gross Margin | 100.00% | 100.00% | - | 100.00% | 100.00% | - | |
Operating Margin | -3929.35% | -3103.48% | - | -4308.68% | -1646.06% | - | |
Profit Margin | -3418.33% | -2759.59% | - | -4392.42% | -3884.33% | - | |
Free Cash Flow Margin | -2975.70% | -2431.77% | - | -4099.28% | -1133.45% | - | |
EBITDA | -38.03 | -32.89 | -59.14 | -47.63 | -17.82 | -20.7 | |
D&A For EBITDA | 0.13 | 0.13 | 0.13 | 0.15 | 0.12 | 0.1 | |
EBIT | -38.15 | -33.02 | -59.27 | -47.78 | -17.93 | -20.8 | |
Revenue as Reported | 0.97 | 1.06 | -0.23 | 1.11 | 1.09 | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.